These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 37223096)

  • 21. Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.
    Aamir S; Anwar MY; Khalid F; Khan SI; Ali MA; Khattak ZE
    Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):e334-e347. PubMed ID: 33573914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.
    Rejeski K; Subklewe M; Aljurf M; Bachy E; Balduzzi A; Barba P; Bruno B; Benjamin R; Carrabba MG; Chabannon C; Ciceri F; Corradini P; Delgado J; Di Blasi R; Greco R; Houot R; Iacoboni G; Jäger U; Kersten MJ; Mielke S; Nagler A; Onida F; Peric Z; Roddie C; Ruggeri A; Sánchez-Guijo F; Sánchez-Ortega I; Schneidawind D; Schubert ML; Snowden JA; Thieblemont C; Topp M; Zinzani PL; Gribben JG; Bonini C; Sureda A; Yakoub-Agha I
    Blood; 2023 Sep; 142(10):865-877. PubMed ID: 37300386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties.
    Haidar G; Garner W; Hill JA
    Curr Opin Infect Dis; 2020 Dec; 33(6):449-457. PubMed ID: 33009139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies.
    Jain T; Knezevic A; Pennisi M; Chen Y; Ruiz JD; Purdon TJ; Devlin SM; Smith M; Shah GL; Halton E; Diamonte C; Scordo M; Sauter CS; Mead E; Santomasso BD; Palomba ML; Batlevi CW; Maloy MA; Giralt S; Smith E; Brentjens R; Park JH; Perales MA; Mailankody S
    Blood Adv; 2020 Aug; 4(15):3776-3787. PubMed ID: 32780846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case Report: Successful engraftment of allogeneic hematopoietic stem cells using CAR-T cell therapy as the conditioning regimen in R/R Ph
    Han L; Zhao R; Yang J; Zu Y; Liu Y; Zhou J; Li L; Huang Z; Zhang J; Gao Q; Song Y; Zhou K
    Front Immunol; 2022; 13():965932. PubMed ID: 36225940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation.
    Cui Q; Qian C; Xu N; Kang L; Dai H; Cui W; Song B; Yin J; Li Z; Zhu X; Qu C; Liu T; Shen W; Zhu M; Yu L; Wu D; Tang X
    J Hematol Oncol; 2021 May; 14(1):82. PubMed ID: 34034795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New-Onset Severe Cytopenia After CAR-T Cell Therapy: Analysis of 76 Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.
    Wang L; Hong R; Zhou L; Ni F; Zhang M; Zhao H; Wu W; Wang Y; Ding S; Chang AH; Hu Y; Huang H
    Front Oncol; 2021; 11():702644. PubMed ID: 34277448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
    Hay KA; Hanafi LA; Li D; Gust J; Liles WC; Wurfel MM; López JA; Chen J; Chung D; Harju-Baker S; Cherian S; Chen X; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2017 Nov; 130(21):2295-2306. PubMed ID: 28924019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to Combine the Two Landmark Treatment Methods-Allogeneic Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Together to Cure High-Risk B Cell Acute Lymphoblastic Leukemia?
    Zhang M; Huang H
    Front Immunol; 2020; 11():611710. PubMed ID: 33384696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
    Zhao A; Zhao M; Qian W; Liang A; Li P; Liu H
    Front Immunol; 2022; 13():1063986. PubMed ID: 36713414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma.
    Xu J; Chen LJ; Yang SS; Sun Y; Wu W; Liu YF; Xu J; Zhuang Y; Zhang W; Weng XQ; Wu J; Wang Y; Wang J; Yan H; Xu WB; Jiang H; Du J; Ding XY; Li B; Li JM; Fu WJ; Zhu J; Zhu L; Chen Z; Fan XF; Hou J; Li JY; Mi JQ; Chen SJ
    Proc Natl Acad Sci U S A; 2019 May; 116(19):9543-9551. PubMed ID: 30988175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery.
    Gutgarts V; Jain T; Zheng J; Maloy MA; Ruiz JD; Pennisi M; Jaimes EA; Perales MA; Sathick J
    Biol Blood Marrow Transplant; 2020 Jun; 26(6):1071-1076. PubMed ID: 32088364
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
    Sterner RC; Sterner RM
    Front Immunol; 2022; 13():879608. PubMed ID: 36081506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
    Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
    Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Feasibility and Safety of CD19 Chimeric Antigen Receptor T Cell Treatment for B Cell Lymphoma Relapse after Allogeneic Hematopoietic Stem Cell Transplantation.
    Schubert ML; Dietrich S; Stilgenbauer S; Schmitt A; Pavel P; Kunz A; Bondong A; Wegner M; Stadtherr P; Jung S; Ho AD; Müller-Tidow C; Schmitt M; Dreger P
    Biol Blood Marrow Transplant; 2020 Sep; 26(9):1575-1580. PubMed ID: 32422254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma.
    Ma S; Li H; Zhou D; Zhang X; Shi M; Cao J; Qi Y; Xia J; Liu Y; Wang X; Li D; Sang W; Yan Z; Zhu F; Sun H; Cheng H; Zheng J; Xu K; Li Z; Qi K; Wang Y
    Cytotherapy; 2023 Jun; 25(6):653-658. PubMed ID: 36907717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
    Li J; Wu Z; Zhao N
    Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.
    Wudhikarn K; Perales MA
    Bone Marrow Transplant; 2022 Oct; 57(10):1477-1488. PubMed ID: 35840746
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy.
    Lindo L; Wilkinson LH; Hay KA
    Front Immunol; 2020; 11():618387. PubMed ID: 33643299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular therapy: Immune-related complications.
    Oved JH; Barrett DM; Teachey DT
    Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.